Manufacturing of Alpha1H for clinical trials is secured
Hamlet Pharma has signed a contract with Rechon Life Science AB for the manufacture of clinical batches of Alpha1H. The batches will be used for continued phase II and future phase III clinical trials in patients with bladder cancer.Hamlet Pharma is committed to the development of the drug candidate Alpha1H for bladder cancer therapy. Larger amounts of drug will be needed for the continued clinical trial program, which involves larger study populations. In order for us to secure drug for the clinical study program, we have signed a contract with Rechon Life Science AB. Rechon is a well